Immunogenomic information displays predictive capability in terms of immunotherapy resistance in metastatic uveal melanoma. @upmchillmancc #oncology #melsm onclive.com/view/immunogen…

Frontline pembrolizumab plus trastuzumab/ chemotherapy improved OS vs placebo plus trastuzumab and chemotherapy in patients with HER2-positive, locally advanced, unresectable or metastatic gastric or GEJ cancer. #oncology #gastriccancer #HER2 onclive.com/view/frontline…

Treatment with EVT801 was well tolerated and led to a stable disease rate of 46% in patients with advanced ovarian cancer. #ovca #oncology #gyncsm onclive.com/view/evt801-is…

The gene therapy nadofaragene firadenovec led to durable antitumor activity in a subset of patients with BCG-unresponsive NMIBC. Vikram M. Narayan, MD Winship Cancer Institute of Emory University #blcsm #MedTwitter #oncology onclive.com/view/nadofarag…

Nadofaragene firadenovec led to durable antitumor activity in BCG-unresponsive NMIBC either with CIS or papillary disease, according to 5-year data from the phase 3 Study CS-003. Vikram M. Narayan, MD Winship Cancer Institute of Emory University #blcsm #MedTwitter #oncology onclive.com/view/nadofarag…

Hear from Arlene O. Siefker-Radtke, MD, of MD Anderson Cancer Center, as she discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer. #blcsm onclive.com/view/dr-siefke…

In this episode of #OncLiveOnAir , Dr. Andre Goy, of JTCancerCenter, discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology. #mmsm #oncology onclive.com/view/goy-gives…

Rezatapopt induced responses with acceptable toxicity in heavily pretreated patients with advanced ovarian cancer harboring TP53 Y220C mutations. Alison Schram SGO #SGOMtg #ovca #oncology onclive.com/view/rezatapop…

Hear from Christian Marth, MD, PhD, as he discusses efficacy and safety findings from the phase 3 LEAP-001 trial in advanced/recurrent endometrial cancer. #gyncsm #oncology onclive.com/view/efficacy-…

ON-DEMAND BROADCAST: Drs. Danilov and Eradat explore data on a novel second-generation BTK inhibitor for adult patients with CLL or SLL. bit.ly/3NftKaE

Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer Wendel Naumann Levine Cancer #ovca #oncology onclive.com/view/naumann-s…

Thank you OncLive.com for highlighting our work with Betsy Koehne Petros Grivas Jonathan L Wright at #AUA24

Second-Line Venetoclax Associated With Real-World Cost Savings vs BTK Inhibitors in CLL/SLL Stanford Medicine JCO Precision Oncology #leusm onclive.com/view/second-li…

Orca-T Offers Favorable Post-Transplant Outcomes in Advanced Hematologic Malignancies City of Hope The EBMT #EBMT24 #oncology onclive.com/view/orca-t-of…

Setanaxib Plus Pembrolizumab Improves Survival in Recurrent/Metastatic HNSCC #hncsm #Oncology onclive.com/view/setanaxib…

Congratulations to Mayo Clinic hematologist and Distinguished Investigator Dr. Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 for his induction into OncLive.com Giants of Cancer Care! His trailblazing work in #MultipleMyeloma has helped forge and advance myeloma care at Mayo Clinic and beyond. bit.ly/4a8Z8Af

Don't miss MedNewsWeek's exciting Keynote Conference, in collaboration with OncLive.com, as we showcase the amazing work of Dr. Krina Patel of MD Anderson Cancer Center discussing the latest in CAR T cell therapy for Multiple Myeloma.

onclive.com/view/earlier-c…

Sylvester Oncologist Contributes to Global Plan to Fight Prostate Cancer @brandonmahal @sylvestercancer @UMiamiMedicine #pcsm
onclive.com/view/sylvester…

FDA Grants Priority Review to Zenocutuzumab BLA for NRG1+ NSCLC and Pancreatic Cancer. #oncology #lcsm #pcsm

onclive.com/view/fda-grant…

FDA Approves Noninvasive Stool RNA Screening Test for CRC onclive.com/view/fda-appro… via @onclive